D
Daniel Castellano
Researcher at Complutense University of Madrid
Publications - 406
Citations - 27374
Daniel Castellano is an academic researcher from Complutense University of Madrid. The author has contributed to research in topics: Medicine & Sunitinib. The author has an hindex of 56, co-authored 345 publications receiving 20327 citations. Previous affiliations of Daniel Castellano include University of Barcelona & Karolinska University Hospital.
Papers
More filters
Journal ArticleDOI
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.
Journal ArticleDOI
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Nizar M. Tannir,David F. McDermott,Osvaldo Arén Frontera,Bohuslav Melichar,Toni K. Choueiri,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Saby George,Thomas Powles,Frede Donskov,V. Neiman,V. Neiman,Christian Kollmannsberger,Pamela Salman,Howard Gurney,Robert E. Hawkins,Alain Ravaud,Marc-Oliver Grimm,Sergio Bracarda,Carlos H. Barrios,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Allen C. Chen,Sabeen Mekan,M. Brent McHenry,Megan Wind-Rotolo,Justin Doan,Padmanee Sharma,Hans J. Hammers,Hans J. Hammers,Bernard Escudier +33 more
TL;DR: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate‐ and poor‐risk patients with previously untreated advanced renal‐cell carcinoma.
Journal ArticleDOI
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg,Jean H. Hoffman-Censits,Thomas Powles,Michiel S. van der Heijden,Arjun Vasant Balar,Andrea Necchi,Nancy A. Dawson,Peter H. O'Donnell,Ani Balmanoukian,Yohann Loriot,Sandy Srinivas,Margitta Retz,Petros Grivas,Richard W. Joseph,Matthew D. Galsky,Mark D. Fleming,Daniel P. Petrylak,Jose Luis Perez-Gracia,Howard A. Burris,Daniel Castellano,Christina Canil,Joaquim Bellmunt,Dean F. Bajorin,Dorothee Nickles,Richard Bourgon,Garrett M. Frampton,Na Cui,Sanjeev Mariathasan,Oyewale O. Abidoye,Gregg Fine,Robert Dreicer +30 more
TL;DR: Treatment with atezolizumab resulted in a significantly improved RECIST v1.1 response rate, compared with a historical control overall response rate of 10%, and Exploratory analyses showed The Cancer Genome Atlas (TCGA) subtypes and mutation load to be independently predictive for response to atezolediazepine.
Journal ArticleDOI
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini,Bernard Escudier,Piotr Tomczak,Andrey Kaprin,Cezary Szczylik,Thomas E. Hutson,M. Dror Michaelson,Vera Gorbunova,Martin Gore,Igor G. Rusakov,Sylvie Negrier,Yen Chuan Ou,Daniel Castellano,Ho Yeong Lim,Hirotsugu Uemura,Jamal Tarazi,David Cella,Connie Chen,Brad Rosbrook,Sinil Kim,Robert J. Motzer +20 more
TL;DR: Axitinib is a treatment option for second-line therapy of advanced renal cell carcinoma and resulted in significantly longer progression-free survival (PFS) compared with sorafenib.
Journal ArticleDOI
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Nicole M. Kuderer,Toni K. Choueiri,Dimpy P. Shah,Yu Shyr,Samuel M. Rubinstein,Donna R. Rivera,Sanjay Shete,Chih-Yuan Hsu,Aakash Desai,Gilberto Lopes,Petros Grivas,Petros Grivas,Corrie A. Painter,Solange Peters,Michael A. Thompson,Ziad Bakouny,Gerald Batist,Tanios Bekaii-Saab,Mehmet Asim Bilen,Nathaniel Bouganim,Mateo Bover Larroya,Daniel Castellano,Salvatore Del Prete,Deborah B. Doroshow,Pamela C Egan,Arielle Elkrief,Dimitrios Farmakiotis,Daniel Blake Flora,Matthew D. Galsky,Michael Glover,Elizabeth A. Griffiths,Anthony P. Gulati,Shilpa Gupta,Navid Hafez,Thorvardur R. Halfdanarson,Jessica Hawley,Emily Hsu,Anup Kasi,Ali Raza Khaki,Ali Raza Khaki,Christopher Lemmon,Colleen Lewis,Barbara Logan,Tyler Masters,Rana R. McKay,Ruben A. Mesa,Alicia K. Morgans,Mary F. Mulcahy,Orestis A. Panagiotou,Prakash Peddi,Nathan A. Pennell,Kerry L. Reynolds,Lane R. Rosen,Rachel P. Rosovsky,Mary Salazar,Andrew Schmidt,Sumit A. Shah,Justin Shaya,John A. Steinharter,Keith Stockerl-Goldstein,Suki Subbiah,Donald C. Vinh,Firas Wehbe,Lisa Weissmann,Julie Tsu Yu Wu,Elizabeth Marie Wulff-Burchfield,Zhuoer Xie,Albert C. Yeh,Albert C. Yeh,Peter Paul Yu,Alice Zhou,Leyre Zubiri,Sanjay Mishra,Gary H. Lyman,Gary H. Lyman,Brian I. Rini,Jeremy L. Warner,Maheen Z. Abidi,Jared D. Acoba,Neeraj Agarwal,Syed A. Ahmad,Archana Ajmera,Jessica K. Altman,Anne H. Angevine,Nilo Azad,Michael H. Bar,Aditya Bardia,Jill S. Barnholtz-Sloan,Briana Barrow,Babar Bashir,Rimma Belenkaya,Stephanie Berg,Eric H. Bernicker,Christine Bestvina,Rohit Bishnoi,Genevieve M. Boland,Mark Bonnen,Gabrielle Bouchard,Daniel W. Bowles,Fiona Busser,Angelo Cabal,Paolo Caimi,Theresa M. Carducci,Carla Casulo,James L. Chen,Jessica M. Clement,David D. Chism,Erin Cook,Catherine Curran,Ahmad Daher,Mark E. Dailey,Saurabh Dahiya,John F. Deeken,George D. Demetri,Sandy DiLullo,Narjust Duma,Rawad Elias,Bryan A. Faller,Leslie A. Fecher,Lawrence E. Feldman,Christopher R. Friese,Paul Fu,Julie Fu,Andy Futreal,Justin F. Gainor,Jorge A. Garcia,David Gill,Erin A. Gillaspie,Antonio Giordano,Grace Glace,Axel Grothey,Shuchi Gulati,Michael J. Gurley,Balazs Halmos,Roy S. Herbst,Dawn L. Hershman,Kent Hoskins,Rohit Jain,Salma K. Jabbour,Alokkumar Jha,Douglas B. Johnson,Monika Joshi,Kaitlin M. Kelleher,Jordan Kharofa,Hina Khan,Jeanna Knoble,Vadim S. Koshkin,Amit Kulkarni,Philip E. Lammers,John C. Leighton,Mark A. Lewis,X. Li,Ang Li,K. M.Steve Lo,Arturo Loaiza-Bonilla,Patricia LoRusso,Clarke A. Low,Maryam B. Lustberg,Daruka Mahadevan,Abdul Hai Mansoor,Michelle Marcum,Merry Jennifer Markham,Catherine Handy Marshall,Sandeep H. Mashru,Sara Matar,Christopher McNair,Shannon K. McWeeney,Janice M. Mehnert,Alvaro G. Menendez,Harry Menon,Marcus Messmer,Ryan Monahan,Sarah Mushtaq,Gayathri Nagaraj,Sarah Nagle,Jarushka Naidoo,John M. Nakayama,Vikram M. Narayan,Heather H. Nelson,Eneida R. Nemecek,Ryan Nguyen,Pier Vitale Nuzzo,Paul E. Oberstein,Adam J. Olszewski,Susie Owenby,Mary M. Pasquinelli,John Philip,Sabitha Prabhakaran,Matthew Puc,Amelie G. Ramirez,Joerg Rathmann,Sanjay G. Revankar,Young Soo Rho,Terence Duane Rhodes,Robert L. Rice,Gregory J. Riely,Jonathan Riess,Cameron Rink,Elizabeth Robilotti,Lori J. Rosenstein,Bertrand Routy,Marc A. Rovito,M. Wasif Saif,Amit Sanyal,Lidia Schapira,Candice Schwartz,Oscar K. Serrano,Mansi R. Shah,Chintan Shah,Grace Shaw,Ardaman Shergill,Geoffrey Shouse,Heloisa P. Soares,Carmen C. Solorzano,Pramod K. Srivastava,Karen Stauffer,Daniel G. Stover,Jamie Stratton,Catherine Stratton,Vivek Subbiah,Rulla M. Tamimi,Nizar M. Tannir,Umit Topaloglu,Eli Van Allen,Susan Van Loon,Karen Vega-Luna,Neeta K. Venepalli,Amit Verma,Praveen Vikas,Sarah Wall,Paul L. Weinstein,Matthias Weiss,Trisha Wise-Draper,William A. Wood,Wenxin Xu,Susan Yackzan,Rosemary Zacks,Tian Zhang,Andrea J. Zimmer,Jack West +239 more
TL;DR: The outcomes of a cohort of patients with cancer and COVID-19 are characterised and potential prognostic factors for mortality and severe illness are identified and race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.